Shares of Metropolis Healthcare Ltd surged 2.86% to ₹2,065.90 on Monday, adding ₹57.50 in early trade. The stock, listed on NSE, has a market capitalisation of ₹10,513.48 crore and has traded between ₹1,315.00 and ₹2,318.30 over the past year.
The diagnostics major, with a strong presence in western and southern India, expects over 12% organic revenue growth in FY26. Managing Director Surendran Chemmenkotil said the growth will be driven by around 7% patient volume increase, 5–6% improvement in realisation, a better product mix, and a 2% price hike implemented earlier this year.
The company began FY26 on a strong note, reporting 23% revenue growth and 19% profit growth in the April–June 2025 quarter. Patient volumes grew 11% at the group level, while the speciality segment jumped 39% (16% standalone). Metropolis posted an EBITDA margin of 24.7% in Q4 FY25 and expects to exceed 25% in FY26, aided by productivity gains and cost optimisation following last year’s lab expansion.
Its TruHealth preventive health check-up business, which has grown 22–25% annually for three years, contributed 18% to revenues last quarter, with a target to reach 20% in the coming quarters.
